Jiangsu Hengrui Medicine Co., Ltd

🇺🇸United States
Ownership
-
Established
1970-01-01
Employees
-
Market Cap
$38.9B
Website
http://www.hrs.com.cn/english/

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2023-07-12
Last Posted Date
2023-10-30
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
100
Registration Number
NCT05942001
Locations
🇨🇳

Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai, Shanghai, China

A Study to Evaluate the Effect of Itraconazole on Pharmacokinetics (PK) of SHR8554 in Healthy Adult Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2023-07-03
Last Posted Date
2023-07-03
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
17
Registration Number
NCT05928988
Locations
🇨🇳

Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China

A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2023-06-22
Last Posted Date
2023-06-28
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
20
Registration Number
NCT05913336
Locations
🇨🇳

The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China

A Study of SHR-A1811 in Subjects With Gynaecologic Oncology

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2023-06-09
Last Posted Date
2023-08-22
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
225
Registration Number
NCT05896020
Locations
🇨🇳

Qilu Hospital of Shandong University, Jinan, Shandong, China

To Compare the Pharmacokinetics and Pharmacodynamics of HR20014, INS068 and INS062 After Single Subcutaneous Injection in Healthy Subjects

First Posted Date
2023-06-05
Last Posted Date
2023-07-20
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
12
Registration Number
NCT05887895
Locations
🇨🇳

The second affiliated hospital of Anhui Medical University, Hefei, Anhui, China

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

First Posted Date
2023-06-01
Last Posted Date
2023-08-09
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
220
Registration Number
NCT05884255
Locations
🇨🇳

Tianjin University Cancer Institute and Hospital, Tianjin, Tianjin, China

A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets

First Posted Date
2023-05-22
Last Posted Date
2023-12-08
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
16
Registration Number
NCT05868057
Locations
🇨🇳

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

First Posted Date
2023-05-18
Last Posted Date
2023-05-18
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
192
Registration Number
NCT05864014

To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability

Phase 1
Completed
Conditions
Interventions
First Posted Date
2023-05-12
Last Posted Date
2023-12-08
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
16
Registration Number
NCT05856058
Locations
🇨🇳

Beijing Hospital, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath